RecruitMe Clinical Trial
SPL-006: An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL- 108 Injections When Used in Combination with Paclitaxel in Patients with Platinum resistant, CD44+, Advanced Ovarian Epithelial Cancer
Study of SPL-108 Injections Used in Combination with Paclitaxel in Patients with Advanced Ovarian Epithelial Cancer
Sponsor: | Splash Pharmaceuticals, Inc. |
Enrolling: | Female Patients Only |
IRB Number: | AAAR9030 |
U.S. Government ID: | NCT03078400 |
Contact: | Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to determine whether SPL-108 injection might be useful for the treatment of ovarian cancer. The study will evaluate whether SPL-108 can slow the growth and spread of cancerous cells in your body. If you agree, you will be treated with SPL-108 injection in combination with paclitaxel and we will collect blood and tissue samples from you before and during the study for laboratory assessment and radiologic assessment will occur as well